Attenuation of lipid peroxidation and atherogenic factors in diabetic patients treated with gliclazide and metformin

Abstract

Background:Diabetes is associated with oxidative stress and considered as a major risk factor for cardiac disease. We attempted to investigate the role of oral antidiabetic (OAD) agents gliclazide and metformin in lowering the lipid peroxidation and managing the risk for cardiovascular (CV) complications in diabetic patients in comparison with nondiabetic healthy individuals.Materials and Methods:This cross-sectional study was comprised of 150 individuals grouped in three, namely, Group A (n = 60) healthy volunteers, Group B (n = 30) newly diagnosed diabetes, and Group C (n = 60) diabetes treated with OAD. Serum malondialdehyde (MDA), nitric oxide (NO), and Vitamin C were assessed for studying lipid peroxidation status, whereas serum triglyceride (TG) and total cholesterol were monitored as predictors for CV risk.Results:We found significantly higher concentrations of MDA and NO levels (P < 0.001) in both groups of patients (Group B and C) in comparison to control group (Group A). Regarding antioxidants, significantly lower concentrations of Vitamin C (P = 0.046) were found in Group B and C compared to Group A. Moreover, there was significant difference exhibited in concentration level of MDA (P = 0.001) and NO (P = 0.015) between Group B and C, whereas difference of Vitamin C (P = 0.147) was not statistically significant.Conclusion:Our data confirmed that treatment with gliclazide and metformin significantly reduced the lipid peroxidation accompanied with attenuated levels of serum TGs and cholesterol and suggested that oral hypoglycemic agents have great impact to reduce the oxidative stress and increase the antioxidant status in diabetes.

Comparative effects of metformin and glibenclamide on the redox balance in type 2 diabetic patients

“…The reductions observed in the enzymatic and nonenzymatic antioxidant levels in the newly diagnosed and glibenclamide groups suggest their excessive utilization in reducing ROS, as demonstrated by increased lipid peroxidation, induced by hyperglycemia (Subash-Babu et al 2014). This observation is consistent with previous studies (Banik et al 2018;Maithili Karpaga Selvi et al 2015). Although glibenclamide group showed a higher catalase level compared to untreated patients, no favorable effect has been found on the MDA level.…”

Alleviation of cisplatin‐induced hepatotoxicity by gliclazide: Involvement of oxidative stress and caspase‐3 activity

“…These findings were consistent with the study of others. 26 Similar to our findings, Alp et al showed that GLZ can reduce the amount of MDA in the peripheral and central nervous system of diabetic rats. 9 GLZ is also able to improve oxidative stress-induced tissue damage in diabetic patients by reducing 8-isoprostane as a marker of lipid oxidation and by increasing antioxidant parameters such as TPAC, SOD, and thiols.…”

“…In this experimental study, 64 male BALB/c mice (25)(26)(27)(28)(29)(30) 15 The animals were kept under standard laboratory conditions (23 ± 2°C, 55 ± 5% moisture, 12:12 h light/dark cycle) with free access to food and water.…”

The association of oxidative stress biomarkers with type 2 diabetes mellitus: a systematic review and meta-analysis

“…Some studies advocated that dietary supplementation of antioxidants like GSH precursor amino acid and antidiabetic drugs like gliclazide and metformin help scavenge the free radicals and reduce oxidative damage in the face of persistent hyperglycemia [33,42,43]. The role of gliclazide and metformin to increase the antioxidant capacity of erythrocyte catalase, GPX, and glutathione Stransferase enzyme in treated patients and reduced the OS in diabetes.…”

“…A total of 5 studies [17,22,29,31] reported the association between TAS levels and T2DM (376 cases and 359 controls) (Table 2), and . A total of 4 studies [19,[31][32][33] reported the association between NO levels and T2DM (217 cases and 176 controls) (Table 2).…”